We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Kywe Kywe
Soe
k.soe@sheffield.ac.uk
Steven
Sourbron
s.sourbron@sheffield.ac.uk
Steven
Sourbron
s.sourbron@sheffield.ac.uk
Diabetes mellitus
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Diabetic kidney disease (DKD) is a common complication of diabetes, and is now the most common form of chronic kidney disease. DKD is the leading cause of kidney disease requiring dialysis or kidney transplantation, and its global incidence and prevalence have reached epidemic levels. While the risk of developing DKD can be ameliorated by tight blood glucose and blood pressure control, it is not fully preventable and once established DKD cannot be cured. Therefore many patients are left with poor and worsening health and with increased mortality risk. Developing new ways to treat DKD requires healthcare professionals to be able to identify those patients most in need of treatment.
One promising approach for identifying patients that are at risk is the use of imaging measurements (called “biomarkers”) derived from Magnetic Resonance Imaging (MRI) and Ultrasound (US) of the kidneys. Evidence from early studies shows that such imaging biomarkers can identify underlying problems in DKD such as blood supply, oxygen supply, kidney scarring and kidney function, in ways that are better than those currently available.
We think that imaging biomarkers will improve the identification of patients who are likely to decline from DKD in the short term. The changes found by imaging may even happen before effects on the blood and urine.
We plan to test this by performing a study observing 500 patients with early stage DKD, recruited in 5 sites across Europe including Leeds. All patients will have detailed assessment at the start of their involvement, including clinical assessment, blood and urine samples, and MRI and US scans. We will look at whether imaging biomarkers are associated with other measures that predict progression in DKD, and follow patients every year for 4 years to see if the imaging biomarkers predict worsening DKD.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Transplantation; On permanent dialysis; Significant comorbidities with life expectancy of < 1 year; Use of investigational drug within 1 month prior to screening; Known clinical history of urinary obstruction on renal US: either post-voiding residue over 100 ml, or pyelectasis; Known clinical history of aortic endoprothesis at the renal level; Current pregnancy; History of Hepatitis B or Hepatitis C +; Use of antiretroviral medication; Known current or clinical history of renal or urinary tract malignancy; Concurrent other renal disease (suspected or proven); Cirrhotic liver disease, or non-cirrhotic chronic liver disease where ALT > 2 x upper limit of normal; Current metastatic malignancy; Current malignancy with expected survival < study follow up period (4 years); Melanomatous skin cancer < 5 years ago (fully resected melanoma > 5 years ago, i.e. surgical cure, can be recruited); Any other significant disease or disorder which, in the opinion of the investigators, may either put the patient at risk because of participation in the study, or may influence the result of the study, or the patient’s ability to participate in the study. Standard MRI exclusions, including: Cochlear Implant; Aneurysm Clips; Neurological stimulator; Implanted cardiac devices (ICD, PPM, loop recorders, or any others); Metal heart valve; History of metal foreign bodies in orbits; Other implanted metal device which prevents MR imaging; Known allergy to Gadolinium contrast; Claustrophobia; Weight exceeding 250 kg.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Steven
Sourbron
s.sourbron@sheffield.ac.uk
Kywe Kywe
Soe
k.soe@sheffield.ac.uk
Steven
Sourbron
s.sourbron@sheffield.ac.uk
The study is sponsored by University of Sheffield and funded by European Commission .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 37691
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
